NCT02976896View on ClinicalTrials.gov

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2022

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Apatinib Mesylate

Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Yuhong Li

OTHER

NCT02976896 - Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment | Biotech Hunter | Biotech Hunter